|Articles|June 1, 2004

Tabloid - Future Goals, Targets, and Treatments of Dyslipidemia
Volume 10
Issue 1 Treat

CME/CE Quiz

Download PDF: CME/CE Quiz

Articles in this issue

over 22 years ago

Article

Blocking intestinal cholesterol absorption for optimal lipid lowering

over 22 years ago

Article

Dual pathway inhibition: Attacking cholesterol on two fronts

over 22 years ago

Article

Beyond ATP III - Impact of recent clinical trials on future lipid management guidelines and therapeutic goals

over 22 years ago

Article

Future Goals, Targets, and Treatments of Dyslipidemia

over 22 years ago

Article

Aggressive lipid lowering superior to usual care in a real-world setting: The ALLIANCE study

over 22 years ago

Article

Managed Care Commentary:MCOs face new challenges

over 22 years ago

Article

Dual inhibition effective and safe in clinical practice: The EASE study

over 22 years ago

Article

Phytosterols may play role in atherosclerosis

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

CME/CE Quiz

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD

5 August FDA Approvals Marked by Novelty, Pushback

Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD

Cross-Trial Vitiligo Data: What Payers Can and Can't Compare

Counseling Vitiligo Patients on Time to Repigmentation